DermTech Secures Billing Codes for its Proprietary Melanoma Test

LA JOLLA, Calif., July 13, 2017 -- (Healthcare Sales & Marketing Network) -- DermTech, Inc., the global leader in non-invasive molecular dermatology, reported today that the American Medical Association (AMA) has granted the company Category 1, Tier 2 Mol... Diagnostics, Oncology, Reimbursement DermTech, Pigmented Lesion Assay, melanoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news